ReviewJournal of the American Academy of Dermatology2026
Atopic dermatitis reconsidered: Clinical mimics and diagnostic pearls.
Review in Journal of the American Academy of Dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin condition with a complex pathogenesis and variable clinical presentation, often overlapping with other dermatologic diseases. This article considers the differential diagnoses for AD, emphasizing the importance of accurately distinguishing it from both common and rare conditions. Among inflammatory dermatoses, seborrheic dermatitis, psoriasis, allergic and irritant contact dermatitis, lichen simplex chronicus, and pityriasis rosea share overlapping features but can be differentiated based on history, distribution, and morphology. Infectious mimickers include scabies, tinea corporis, impetigo, and secondary syphilis, each with unique clinical or diagnostic markers. High priority diagnoses such as neoplastic diseases (mycosis fungoides), autoimmune conditions (dermatomyositis), nutritional deficiencies (zinc, niacin), genetic syndromes (Netherton, severe dermatitis-allergies-metabolic wasting), primary immunodeficiencies (hyper-IgE, DiGeorge, Wiskott-Aldrich syndrome), and drug eruptions require special consideration. Despite growing interest in immunologic and molecular biomarkers for AD, no single biomarker offers diagnostic certainty. Advances in diagnostic tools such as epidermal profiling and RNA sequencing may pave the way for more personalized approaches to dermatologic care. Currently, accurate diagnosis of AD remains clinical and requires vigilance, especially when disease course and response to therapy deviate from expected patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.